Drug companies should drop their patents and collaborate to fight coronavirus

As the coronavirus pandemic continues to claim victims around the world, the race is on to produce the right medicines to fight it. This includes developing a vaccine to stop people from falling ill in the first place, testing kits and drugs to treat those that fall ill with COVID-19.

Cellmid secures China patent coverage for hair loss

Bio-technology developer Cellmid has secured patent coverage for its Evolis anti-ageing hair care and hair loss products in the potentially large China market. The Chinese Patent Office has issued notification of its grant of the patent “method of treatment of Alopecia with Monoterpenoids.” Monoterpenoids are a class of terpenes found in botanical extracts and formulated…

Orthocell receives $2.9 million R&D refund

Nerve technology developer Orthocell (ASX:OCC) has received a $2.9 million R&D tax incentive refund for the 2018/19 financial year. The Perth company, which is commercialising its CelGro product to facilitate the regeneration of severed peripheral nerves, will invest the funds to accelerate regulatory approvals and to advance R&D. The company also recently raised new capital…